{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T01:08:52Z","timestamp":1787879332512,"version":"build-2784847793"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"vor","delay-in-days":144,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","award":["AP153362014"],"award-info":[{"award-number":["AP153362014"]}],"id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clim.2021.108792","type":"journal-article","created":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T23:26:16Z","timestamp":1625181976000},"page":"108792","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation"],"prefix":"10.1016","volume":"229","author":[{"given":"Olga","family":"Mill\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Rovira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lluis","family":"Guirado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klemens","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Sommerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston J.","family":"Pi\u00f1eiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Diekmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merc\u00e8","family":"Brunet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.clim.2021.108792_bb0005","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/FTD.0000000000000287","article-title":"Barcelona consensus on biomarker-based immunosuppressive drugs management in solid organ transplantation","volume":"38","author":"Brunet","year":"2016","journal-title":"Ther. Drug Monit."},{"issue":"2","key":"10.1016\/j.clim.2021.108792_bb0010","first-page":"53","article-title":"Urinary CXCL9 and CXCL10 levels and acute renal graft rejection","volume":"10","author":"Ciftci","year":"2019","journal-title":"Int. J. Organ TX Med."},{"key":"10.1016\/j.clim.2021.108792_bb0015","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40697-015-0061-x","article-title":"Developing renal allograft surveillance strategies - urinary biomarkers of cellular rejection","volume":"2","author":"Hirt-Minkowski","year":"2015","journal-title":"Can. J. Kidney Health Dis."},{"key":"10.1016\/j.clim.2021.108792_bb0020","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/j.1600-6143.2011.03680.x","article-title":"Urinary chemokines CXCL9 and CXCL10 are noninvasive markers of renal allograft rejection and BK viral infection","volume":"11","author":"Jackson","year":"2011","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.clim.2021.108792_bb0025","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1111\/bcp.13399","article-title":"Urinary miR-155-5p and CXCL10 as prognostic and predictive biomarkers of rejection, graft outcome and treatment response in kidney transplantation","volume":"83","author":"Mill\u00e1n","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.clim.2021.108792_bb0030","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1038\/sj.ki.5000343","article-title":"Early post-transplant urinary IP-10 expression after kidney transplantation is predictive of short- and long-term graft function","volume":"69","author":"Matz","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.clim.2021.108792_bb0035","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/ajt.13677","article-title":"Early low urinary CXCL9 and CXCL10 might predict immunological quiescence in clinically and histologically stable kidney recipients","volume":"16","author":"Rabant","year":"2016","journal-title":"Am. J. Transplant."},{"issue":"7","key":"10.1016\/j.clim.2021.108792_bb0040","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1097\/TP.0000000000002560","article-title":"The impact of early clinical and subclinical T cell-mediated rejection after kidney transplantation","volume":"103","author":"Hoffman","year":"2019","journal-title":"Transplantation"},{"issue":"6","key":"10.1016\/j.clim.2021.108792_bb0045","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1097\/TP.0000000000002682","article-title":"Subclinical inflammation in renal transplantation","volume":"103","author":"Rush","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2021.108792_bb0050","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1681\/ASN.2014080797","article-title":"Urinary C-X-C motif chemokine 10 independently improves the noninvasive diagnosis of antibody-mediated kidney allograft rejection","volume":"26","author":"Rabant","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.clim.2021.108792_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.trre.2016.10.004","article-title":"Acute antibody-mediated rejection in kidney transplant recipients","author":"Davis","year":"2017","journal-title":"Transplant. Rev. (Orlando)"},{"key":"10.1016\/j.clim.2021.108792_bb0060","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1097\/TP.0000000000001040","article-title":"Within-patient variability in tacrolimus blood levels predicts kidney graft loss and donor-specific antibody development","volume":"100","author":"Rodrigo","year":"2016","journal-title":"Transplanataion"},{"key":"10.1016\/j.clim.2021.108792_bb0065","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.clim.2021.108792_bb0070","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/TP.0000000000001931","article-title":"Urinary CXCL10 chemokine is associated with Alloimmune and virus compartment-specific renal allograft inflammation","volume":"102","author":"Ho","year":"2018","journal-title":"Transplantation"},{"issue":"8","key":"10.1016\/j.clim.2021.108792_bb0075","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/TP.0b013e318210de6b","article-title":"Pretransplant serum CXCL9 and CXCL10 levels fail to predict acute rejection in kidney transplant recipients receiving induction therapy","volume":"91","author":"Heidt","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2021.108792_bb0080","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1097\/01.TP.0000160759.85080.2E","article-title":"High CXCL10 expression in rejected kidneys and predictive role of Pretransplant serum CXCL10 for acute rejection and chronic allograft nephropathy","volume":"79","author":"Lazzeri","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2021.108792_bb0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trim.2018.08.003","article-title":"Multiple-biomarkers provide powerful prediction of early acute renal allograft rejection by combination of serum Fractalkine, IFN-\u03b3 and IP-10","volume":"50","author":"Xu","year":"2018","journal-title":"Transpl. Immunol."},{"key":"10.1016\/j.clim.2021.108792_bb0090","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1097\/TP.0000000000002366","article-title":"A 2018 reference guide to the Banff classification of renal allograft pathology","volume":"102","author":"Roufosse","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2021.108792_bb0095","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ajt.14625","article-title":"The Banff 2017 kidney meeting report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials","volume":"18","author":"Haas","year":"2018","journal-title":"Am. J. Transplant."},{"issue":"3","key":"10.1016\/j.clim.2021.108792_bb0100","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13798","article-title":"Management of BK viremia is associated with a lower risk of subsequent cytomegalovirus infection in kidney transplant recipients","volume":"34","author":"Jorgenson","year":"2020","journal-title":"Clin. Transpl."},{"issue":"9","key":"10.1016\/j.clim.2021.108792_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.13528","article-title":"BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Hirsch","year":"2019","journal-title":"Clin. Transpl."},{"issue":"12","key":"10.1016\/j.clim.2021.108792_bb0110","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMoa1714656","article-title":"Maribavir for preemptive treatment of cytomegalovirus reactivation","volume":"381","author":"Maertens","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2021.108792_bb0115","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/FTD.0b013e31815f5416","article-title":"Limited sampling strategy for simultaneous estimation of the area under the concentration-time curve of tacrolimus and mycophenolic acid in adult renal transplant recipients","volume":"30","author":"Miura","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clim.2021.108792_bb0120","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1093\/ndt\/gfp162","article-title":"The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the symphony pharmacokinetic substudy","volume":"24","author":"Grinyo","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.clim.2021.108792_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","volume":"143","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"10.1016\/j.clim.2021.108792_bb0130","first-page":"32","article-title":"Index for ratting diagnosis test","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.clim.2021.108792_bb0135","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungmann","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.clim.2021.108792_bb0140","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fmed.2020.00114","article-title":"Non-invasive chemokine detection: improved prediction of antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients","volume":"7","author":"M\u00fchlbacher","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.clim.2021.108792_bb0145","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1111\/j.1600-6143.2006.01436.x","article-title":"The significance of subclinical rejection and the value of protocol biopsies","volume":"6","author":"Nankivell","year":"2006","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.clim.2021.108792_bb0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/TP.0b013e31823bb647","article-title":"Early subclinical rejection as a risk factor for late chronic humoral rejection","volume":"93","author":"Moreso","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2021.108792_bb0155","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1097\/TP.0b013e31822d4de1","article-title":"Validation of urinary CXCL10 as a marker of borderline, subclinical, and clinical Tubulitis","volume":"92","author":"Ho","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2021.108792_bb0160","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1097\/TP.0000000000000419","article-title":"Elevated urinary CXCL10-to-creatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation","volume":"99","author":"Blydt-Hansen","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.clim.2021.108792_bb0165","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/tri.12251","article-title":"Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation","volume":"27","author":"Schachtner","year":"2014","journal-title":"Transpl. Int."},{"key":"10.1016\/j.clim.2021.108792_bb0170","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/tri.13584","article-title":"Longitudinal assessment of the CXCL10 blood and urine concentration in kidney transplant recipients with BK polyomavirus replication-a retrospective study","volume":"33","author":"Weseslindtner","year":"2020","journal-title":"Transpl. Int."},{"issue":"12","key":"10.1016\/j.clim.2021.108792_bb0175","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1111\/ajt.15959","article-title":"Development and validation of an optimized integrative model using urinary chemokines for noninvasive diagnosis of acute allograft rejection","volume":"20","author":"Tinel","year":"2020","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.clim.2021.108792_bb0180","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/ajt.13803","article-title":"High Intrapatient variability of tacrolimus concentrations predicts accelerated progression of chronic histologic lesions in renal recipients","volume":"16","author":"Vanhove","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.clim.2021.108792_bb0185","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation."},{"key":"10.1016\/j.clim.2021.108792_bb0190","doi-asserted-by":"crossref","first-page":"5201098","DOI":"10.1155\/2017\/5201098","article-title":"From humoral theory to performant risk stratification in kidney transplantation","volume":"2017","author":"Lefaucheur","year":"2017","journal-title":"J Immunol Res"},{"key":"10.1016\/j.clim.2021.108792_bb0195","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.clim.2021.108792_bb0200","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","author":"Brunet","year":"2019","journal-title":"Ther. Drug Monit."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621001297?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661621001297?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:03:50Z","timestamp":1761494630000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661621001297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":40,"alternative-id":["S1521661621001297"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2021.108792","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advantages of plasmatic CXCL-10 as a prognostic and diagnostic biomarker for the risk of rejection and subclinical rejection in kidney transplantation","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2021.108792","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108792"}}